First-line squamous NSCLC: A high unmet need for survival improvements in this patient population1-5
In first-line squamous NSCLC, there have been no additional survival improvements for ~20 years2-5
The history of OS improvements in first-line squamous NSCLC*
*This representation is based on review articles that include many trials and does not account for differences in patient populations, dosing regimens, or trial design. This information is provided for illustrative historical purposes only and should not be used for any clinical assessment or decision regarding specific therapies.
- 87% of patients with squamous NSCLC have at least 1 comorbidity6
- The majority of squamous NSCLC tumors are centrally located close to blood vessels, which can lead to potentially fatal complications7,8
- Compared with adenocarcinoma, the major histologic subtype of nonsquamous NSCLC, EGFR mutations and ALK fusions occur less frequently in squamous NSCLC9-12:
- EGFR mutation: 15%-20% vs <5%, respectively
- ALK fusion: 3%-7% vs <5%, respectively
NSCLC=non-small cell lung cancer; OS=overall survival; EGFR=epidermal growth factor receptor; ALK=anaplastic lymphoma kinase.
The Lancet® is a registered trademark of Reed Elsevier Properties S.A.
References: 1. Oliver TG, Patel J, Akerley W. Squamous non-small cell lung cancer as a distinct clinical entity. Am J Clin Oncol. 2015;38(2):220-226. 2. Kuribayashi K, Tabata C. Cutting-edge medical treatment for advanced non-small cell lung cancer. J Cancer Biol Res. 2014;2(1):1026. 3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92-98. 4. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002;20(21):4285-4291. 5. Ellis LM, Bernstein DS, Voest EE, et al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014;32(12):1277-1280. 6. Data on file. Lilly Research Laboratories (ONC20150827a). 7. Rosado-de-Christenson ML, Templeton PA, Moran CA. Bronchogenic carcinoma: radiologic-pathologic correlation. Radiographics. 1994;14(2):429-446. 8. Nichols L, Saunders R, Knollmann FD. Causes of death of patients with lung cancer. Arch Pathol Lab Med. 2012;136(12):1552-1557. 9. Gerber DE, Gandhi L, Costa DB. Management and future directions in non-small cell lung cancer with known activating mutations. Am Soc Clin Oncol Educ Book. 2014:e353-e365. 10. Rose-James A, Sreelekha TT. Molecular markers with predictive and prognostic relevance in lung cancer. Lung Cancer Int.. 2012;2012:1-12. 11. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12(2):175-180. 12. Perez-Moreno P, Brambilla E, Thomas R, Soria JC. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res. 2012;18(9):2443-2451.
Lilly PatientOne Co-pay Program:
See if your patients qualify
Explore the range of patients included in the SQUIRE trial
Help patients manage their skin and nails during treatment
Explore the results of the SQUIRE trial
Thoracic Treatment Talk:
Watch Ed Kim, MD, FACP, discuss Portrazza, a treatment option for your patients with metastatic squamous NSCLC
Learn more about the recommended dosing and administration of Portrazza
Learn more about dose modifications with Portrazza
Learn more about the incidence of dermatologic toxicities with Portrazza plus gemcitabine and cisplatin
View the incidence of electrolyte abnormalities with Portrazza plus gemcitabine and cisplatin
View the adverse reactions of Portrazza plus gemcitabine and cisplatin
High Unmet Need:
Review the unmet need in first-line squamous NSCLC
A multicenter, phase III trial in 1093 patients
Explore the results of the trial by using your login information at The Lancet®
Find out how Lilly PatientOne may provide financial assistance for eligible patients